CCL18在卵巢癌组织及血清中的表达分析

Analysis of CCL18 expression in ovarian cancer tissue and serum

目的研究CCL18在卵巢癌组织及血清中的表达情况,探讨其作为卵巢癌新型标志物的临床价值。方法 RTPCR检测63例卵巢癌组织及58例卵巢良性肿瘤组织CCL18 mRNA表达;ELISA法检测各组织标本相应血清中CCL18分泌蛋白表达浓度,以健康体检人群作为对照。结果卵巢癌组织中CCL18 mRNA阳性表达率为50.68%;卵巢良性肿瘤组织中CCL18 mRNA阳性率为27.59%。卵巢癌组织中CCL18 mRNA相对表达水平明显高于卵巢良性疾病者,差异有统计学意义(P<0.01);卵巢癌患者血清中CCL18浓度显著高于卵巢良性肿瘤患者和健康体检者,差异有统计学意义(P<0.01);在卵巢癌患者血清中,CCL18浓度与临床分期和淋巴结转移相关。结论 CCL18在卵巢癌组织和血清中高表达,且可为卵巢癌临床分期和淋巴结是否转移提供参考价值,具有成为新型卵巢癌标志物的可能性。

Objective To explore the CCL18 expression in ovarian cancer tissues and serum,and to investigate the diagnostic value of CCL18 in the detection of ovarian cancer. Methods RT-PCR was used to detect the expression of CCL18 mRNA in the patients with 63 cases ovarian cancer and 58 cases benign ovarian lesions. Enzyme-linked immunosorbent assay（ ELISA）method was used to detect the expression levels of CCL18 secreted protein in the serum of each tissue sample,with healthy people as the control group. Results The positive rate of CCL18 mRNA in ovarian cancer tissue was 50. 68%,and that of benign ovarian lesions tissue was 27. 59%; the CCL18 mRNA levels in ovarian cancer tissue were obviously higher than that of benign ovarian lesions,with the difference statistically significant（ P 〈 0. 01）. The concentration of serum CCL18 in ovarian cancer were dramatically higher than that of benign ovarian cancer and the controls,with the differences statistically significant（ P 〈0. 01）; in the serum of ovarian cancer patients,CCL18 concentration was positively correlated with clinical stage and lymph node metastasis. Conclusion The expression of CCL18 was higher in ovarian cancer tissue and serum,and it can provide reference for clinical stage and lymph node metastasis of ovarian cancer,and it has become a new marker of ovarian cancer.